临床外科杂志 ›› 2026, Vol. 34 ›› Issue (8): 904-907.doi: 10.3969/j.issn.1005-6483.20250672

• 论著 • 上一篇    下一篇

膀胱癌病人术前血清胱抑素6、着丝粒蛋白A、C型凝集素结构域家族3成员B水平检测的临床意义

  

  1. 041000  山西临汾，临汾市人民医院泌尿外科
  • 收稿日期:2025-06-26 接受日期:2025-06-26 出版日期:2026-08-20 发布日期:2026-08-20
  • 通讯作者: 朱国熙，Email：wyijuo@163.com
  • 基金资助:
    临汾市科技重点研发计划资助项目（1914）

Clinical significance of preoperative detection of serum cystatin 6,centromere protein A and C-lectin domain family 3 member B levels in patients with bladdercancer

  1. Department of Urology,Linfen People's Hospital,Linfen 041000,China
  • Received:2025-06-26 Accepted:2025-06-26 Online:2026-08-20 Published:2026-08-20

PDF (PC)

17

PDF (Mobile)

2

摘要： 目的 分析膀胱癌病人术前血清胱抑素6（CST6）、着丝粒蛋白A（CENPA）、C-型凝集素结构域家族3成员B（CLEC3B）水平与其临床特征及预后的关系。方法 收集2020年1月~2021年12月接受治疗的膀胱癌病人160例为癌症组，以同期160例健康体检者为对照组。采用酶联免疫吸附法检测血清CST6、CENPA、CLEC3B水平，受试者工作特征（ROC）曲线分析血清CST6、CENPA、CLEC3B预测膀胱癌预后的价值；血清CST6、CENPA、CLEC3B与预后的关系采用Kaplan-Meier法分析。结果 癌症组病人CST6、CENPA水平分别为（7.65±1.59）ng/ml 、（15.41±4.67） ng/ml， 高于对照组的（3.24±0.97） ng/ml、（8.92±2.63）ng/ml ，癌症组CLEC3B为（67.29±13.25） ng/ml，低于对照组的（95.35±15.96）ng/ml ，两组比较差异统计学有意义（P<0.05）。不同分化程度、T分期、淋巴结转移病人血清CST6、CENPA、CLEC3B水平比较，差异有统计学意义（P<0.05）。预后不良组CST6、CENPA水平高于预后良好组，CLEC3B低于预后良好组，两组比较，差异有统计学意义（P<0.05）。ROC曲线分析结果显示，CST6、CENPA、CLEC3B三者联合预测病人预后的曲线下面积（AUC）为0.926，明显高于三者单独预测。Kaplan-Meier分析结果显示，血清CST6、CENPA、CLEC3B高低表达者累积生存率差异显著（Log Rank χ2=11.102、15.817、36.612，P<0.001）。结论 CST6、CENPA、CLEC3B均与膀胱癌病人临床特征及预后有关，三者联合用于膀胱癌预后预测的价值较高，并与膀胱癌术后总生存率有关。

关键词: 膀胱癌, 胱抑素6, 着丝粒蛋白A, C-型凝集素结构域家族3成员B

Abstract: Objective To analyze the relationship between preoperative serum cystatin 6 (CST6),centromere protein A (CENPA),C-type lectin domain family 3 member B (CLEC3B) and clinical features and prognosis in bladder cancer.Methods From January 2020 to December 2021,160 patients with bladder cancer who were treated in our hospital were collected for research (cancer group),and 160 healthy people were served as control group.The levels of serum CST6,CENPA and CLEC3B were detected by enzymelinked immunosorbent assay.The receiver operating characteristic (ROC) curve was used to analyze the value of serum CST6,CENPA and CLEC3B in predicting the prognosis of bladder cancer.The relationship between serum CST6,CENPA,CLEC3B and prognosis was analyzed using the Kaplan-Meier-method.Results The levels of CST6 and CENPA in the cancer group were (7.65±1.59) ng/ml and (15.41±4.67) ng/ml respectively,which were higher than those in the control group [(3.24±0.97) ng/ml and (8.92±2.63) ng/ml].The CLEC3B in the cancer group was (67.29±13.25) ng/ml,which was lower than that in the control group [(95.35±15.96) ng/ml],and the difference between the two groups was statistically significant (P<0.05).The serum CST6,CENPA,and CLEC3B was statistically clearly different among different differentiation,T staging,and lymph node metastasis (P<0.05).The poor prognosis group had higher CST6 and CENPA,and lower CLEC3B than good prognosis group (P<0.05).The ROC curve showed that the area under the curve (AUC) of the combined prediction of patient prognosis by CST6,CENPA and CLEC3B was 0.926,which was significantly higher than that of the individual predictions of the three.Kaplan-Meier analysis showed that there were significant differences in cumulative survival rates among those with high and low expressions of serum CST6,CENPA,and CLEC3B (Log Rankχ2=11.102,15.817,36.612,all P<0.001).Conclusion CST6,CENPA and CLEC3B are all related to the clinical characteristics and prognosis of patients with bladder cancer.The combination of the three has a high value in predicting the prognosis of bladder cancer and is related to the overall survival rate after bladder cancer surgery.

Key words: bladder cancer, cystatin 6, centromere protein A, C-type lectin domain family 3 member B

[1] 杨晓伟 王雷雨 胡春晖 赵先诚 邓鑫 张前进. 经尿道膀胱肿瘤切除术后尿道感染的病原菌特点及风险预测模型[J]. 临床外科杂志, 2026, 34(3): 331-336.
[2] 邓鑫 郁全胜 王雷雨 陈猛 刘豪. 非肌层浸润性膀胱癌病人血清内皮细胞特异性分子-1、胆碱酯酶、鸢尾素水平与膀胱灌注治疗后复发的关系[J]. 临床外科杂志, 2026, 34(2): 218-222.
[3] 杨林 韩玉刚 梁想. 膀胱癌组织中微小RNA-433-3p、β微管蛋白V的表达与病理特征的关系及对术后复发的预测价值[J]. 临床外科杂志, 2025, 33(2): 175-178.
[4] 李凡, 杨为民. 2024美国泌尿外科学会/泌尿肿瘤学会膀胱癌诊疗指南更新解读[J]. 临床外科杂志, 2025, 33(1): 59-62.
[5] 路慧青 赵友为 刘巍. 膀胱癌病人血清miR-143-3p、ATG2B水平与临床病理及预后生存的关系[J]. 临床外科杂志, 2024, 32(7): 757-761.
[6] 孙飞 周家权 王飞. 组织RNA聚合酶III亚基G表达增加预测肌层浸润性膀胱癌辅助化疗反应和预后不良[J]. 临床外科杂志, 2023, 31(8): 763-767.
[7] 梁博 何跃 刘泓键 奉友刚 何俊. 膀胱癌组织中miR-144、肺癌转移相关转录本1及睾丸蛋白聚糖表达及其诊断价值[J]. 临床外科杂志, 2023, 31(5): 440-443.
[8] 管富勇 王黎 王俊霖 姚启盛. 非肌层浸润性膀胱癌经尿道膀胱肿瘤电切术后肿瘤残余病人行二次电切术后复发的危险因素分析[J]. 临床外科杂志, 2023, 31(2): 127-131.
[9] 陈勇伟 李昊 黄力 陈从波 王黎 姚启盛. 新辅助化疗联合经尿道膀胱肿瘤电切术对膀胱癌病人肿瘤直径、尿液膀胱肿瘤抗原水平及复发率的影响[J]. 临床外科杂志, 2023, 31(2): 152-155.
[10] 梁峰 丁俊 孙建鸣 刘俊强 张超. 经尿道膀胱肿瘤等离子整块剜除术对非肌层浸润性膀胱癌患者排尿功能、血清YKL-40、BLCA-1、PON-1水平的影响[J]. 临床外科杂志, 2023, 31(11): 1088-1092.
[11] 王亚彬 林英立. 核糖蛋白1对非肌层浸润膀胱癌术后复发的预测作用[J]. 临床外科杂志, 2023, 31(10): 974-977.
[12] 刘琦 万玉文 李晓强. 椎管内麻醉联合超声引导下闭孔神经阻滞与全身麻醉相比对经尿道膀胱肿瘤切除术病人术后肿瘤复发影响的临床研究进展[J]. 临床外科杂志, 2022, 30(6): 506-509.
[13] 姚宝春 邓大溢 方强 陈士洲. 激光与电切术治疗非肌层浸润性膀胱癌的疗效及应激反应程度比较[J]. 临床外科杂志, 2022, 30(6): 579-582.
[14] 张顺 丁秋播 庄君龙. 膀胱癌新辅助免疫治疗引起免疫相关性膀胱炎二例[J]. 临床外科杂志, 2022, 30(3): 276-279.
[15] 李玉柱 夏连杰. 膀胱癌病人癌组织中Dickkopf相关蛋白2的表达及与预后的相关性[J]. 临床外科杂志, 2022, 30(3): 280-283.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 邱江. 心脏死亡捐献供肾移植免疫抑制方案的选择[J]. 临床外科杂志, 2016, 24(10): 735 .
[2] 陈忠;王耀东;田毅峰;等. 肝胆管结石病规范化治疗的临床分析[J]. 临床外科杂志, 2016, 24(10): 753 .
[3] 石汉平. 胃癌围手术期营养治疗[J]. 临床外科杂志, 2016, 24(11): 821 .
[4] 王维君;那光玮;何科基;等. 根治性淋巴结清扫联合脾切除在残胃癌手术中的临床意义探究[J]. 临床外科杂志, 2016, 24(11): 835 .
[5] 李阳;胡元祥;胡季明;等. 甲状腺结核11例临床分析[J]. 临床外科杂志, 2016, 24(11): 888 .
[6] 殷刚;罗良弢;严想元. 加ω-3脂肪酸全肠外营养对肠梗阻术后患者肠黏膜屏障功能的影响[J]. 临床外科杂志, 2016, 24(12): 916 .
[7] 王峻;徐亚青;刘仁忠 . 丙氨酰谷氨酰胺注射液配合肠内、外营养对神经外科术后颅内感染患者营养状态及免疫功能的影响[J]. 临床外科杂志, 2016, 24(12): 919 .
[8] 邹长林;许州;刘超;等. 单侧额下入路显微切除大型及巨大型嗅沟脑膜瘤[J]. 临床外科杂志, 2016, 24(12): 946 .
[9] 李波 赵智刚 唐忠志 . 严重创伤合并创伤性凝血病的临床治疗分析 [J]. 临床外科杂志, 2016, 24(4): 302 - 302 .
[10] 张华园;高峰;董军等. 颅内多发脑膜瘤一例[J]. 临床外科杂志, 2016, 24(4): 319 .
版权所有 © 《临床外科杂志》编辑部
地址：武汉市武昌区东湖路165号　邮编：430071　电话：027-87893476　E-mail: whlcwk@126.com
本系统由北京玛格泰克科技发展有限公司设计开发
鄂ICP备11011458号-3